3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
10
Breast Neoplasms
9
Prostatic Neoplasms
7
Multiple Myeloma
6
Colorectal Neoplasms
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Leukemia, Myeloid, Acute
4
Head and Neck Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Recurrence
3
Neoplasms, Plasma Cell
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Urinary Bladder Neoplasms
2
Neoplasms by Site
2
Mycoses
2
Medication Adherence
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Leukemia
2
Carcinoma, Transitional Cell
2
COVID-19
2
Adenocarcinoma
2
Uveal Melanoma
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Interventions
Gemcitabine
11
Cisplatin
10
pembrolizumab
7
Fluorouracil
3
Drug Therapy
3
spartalizumab
2
derazantinib
2
Leucovorin
2
trametinib
1
tislelizumab
1
silmitasertib
1
seribantumab
1
pertuzumab
1
olutasidenib
1
galactomannan
1
exatecan
1
durvalumab
1
becatecarin
1
Tegafur
1
Standard of Care
1
S 1 (combination)
1
Ritonavir
1
Quality of Life
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
Observation
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Microscopy, Confocal
1
Melphalan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Bile Duct Neoplasms
×
Standard of Care
×
Clear all
NCT04099888
2023-09-11
RELEASE
PCI Biotech AS
Phase 2
Terminated
41 enrolled
17 charts